Tango Therapeutics TNGX 深 滬
等待開盤 08-20 09:30:00 美东时间
6.96
-0.260
-3.60%
華盛通- 最 高7.42
- 今 開7.35
- 成交量 285.19万股
- 最 低 6.63
- 昨 收 7.22
- 總市值 7.52亿
- 52周最高 11.92
- 市盈率 靜 --
- 換手率 2.64%
- 52周最低 1.03
- 委 比 6.64%
- 總股本 1.08亿
- 歷史最高 18.84
- 量 比 2.23
- 振 幅 10.94%
- 歷史最低 1.03
- 每 手 1
- 風險率 1.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Piper Sandler Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $11
Piper Sandler analyst Kelsey Goodwin initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Overweight rating and announces Price Target of $11.
08-19 19:51
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Tango Therapeutics reported Q2 2025 financials with $3.2M collaboration revenue and $32.8M R&D expenses. The company highlighted progress in its PRMT5 inhibitor pipeline, including TNG462 in combination trials with Revolution Medicines' RAS(ON) inhibitors and TNG456 for glioblastoma. Upcoming milestones include clinical updates for TNG462 and TNG260 in H2 2025. Cash reserves of $180.8M are expected to fund operations into early 2027.
08-05 11:00
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
Tango Therapeutics announced it will release its second quarter 2025 financial results on August 5, 2025, before U.S. markets open, without hosting a conference call. The company focuses on discovering novel cancer drug targets using synthetic lethality principles.
07-22 11:00
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
Tango Therapeutics announced the initiation of a Phase 1/2 trial for TNG462 in combination with daraxonrasib or zoldonrasib for MTAP-deleted, RAS-mutant pancreatic or lung cancer. Preclinical data show strong combination activity, and single-agent data demonstrate tolerability and efficacy in these cancers. The trial aims to assess safety, pharmacokinetics, and antitumor activity. TNG462, a potential best-in-class PRMT5 inhibitor, is also being e...
06-27 11:00
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining more ...
06-16 20:38
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on ...
06-06 22:20
美股牛股 | “英伟达亲儿子”CoreWeave涨超25%，公司签下70亿美元大单；能源股VG绩后大涨21%
“英伟达亲儿子”CoreWeave涨超25%，公司签下70亿美元大单；能源股VG绩后大涨21%，Q1营收大增超100%>>
06-04 19:21
美股牛股 | 中概妖股大爆发！脑再生科技月内狂涨11倍，尚乘数科单日大涨34%
中概妖股大爆发！脑再生科技月内狂涨11倍，尚乘数科单日涨超34%；C3.ai季报超预期，股价绩后涨逾20%>>
05-30 19:20
纳斯达克生物科技指数收涨超2%
成分股Oric Pharma收涨33.50%，Erasca涨32.73%，Tango Therapeutics涨20.10%表现第三。莱斯康制药（LXRX）则收...
05-30 04:44
